Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

por Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Publicado 2021

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

por Shiliang Huang, Joel E. Michalek, David A. Reardon, Patrick Y. Wen, John R. Floyd, Peter T. Fox, Geoffrey D. Clarke, Paul A. Jerabek, Kathleen M. Schmainda, Mark Muzi, Hyewon Hyun, Eudocia Quant Lee, Andrew J. Brenner
Publicado 2021